Rigel Pharmaceuticals (RIGL) Stock Highlights

0.98 | -3.92%

2024-05-11 03:08:10

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firms lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Statistics

Range Today

0.97 1.02

Volume Today 996.8K

Range 1 Year

0.71 1.96

Volume 1 Year 359.25M

Range 3 Year

0.64 4.62

Volume 3 Year 1.82B

Range 10 Year

0.64 5.5

Volume 10 Year 4.88B

Highlights

Market Capitalization 172.67M (small)

Floating Shares 146.98M

Current Price 0.98

Price To Earnings -7.21

Price To Revenue 1.88

Earnings Per Share -0.14

Payout Ratio 0%

Performance

Latest -3.92%

1 Month -21.6%

3 Months -18.33%

6 Months +19.51%

1 Year -15.52%

3 Years -70.75%

5 Years -56.05%

10 Years -65.97%

Benchmarks

Market Capitalization

211 / 368

Gross Profits

62 / 278

Total Revenue

81 / 300

Total Rank

35 / 368

Free Cashflow

150 / 352

Performance 5 years

197 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.